Q1 Earnings Forecast for HRTX Issued By Northland Securities

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at Northland Securities dropped their Q1 2026 EPS estimates for Heron Therapeutics in a research report issued on Thursday, March 26th. Northland Securities analyst C. Byrnes now expects that the biotechnology company will post earnings of ($0.02) per share for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

A number of other brokerages also recently issued reports on HRTX. Zacks Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a report on Friday, January 9th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.50.

Heron Therapeutics Price Performance

Shares of HRTX opened at $0.75 on Monday. The company has a current ratio of 2.48, a quick ratio of 1.51 and a debt-to-equity ratio of 10.59. The stock’s 50 day moving average is $1.12 and its two-hundred day moving average is $1.21. Heron Therapeutics has a twelve month low of $0.74 and a twelve month high of $2.61. The firm has a market capitalization of $140.63 million, a PE ratio of -5.74 and a beta of 1.26.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The firm had revenue of $40.59 million for the quarter, compared to analysts’ expectations of $39.53 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Clearline Capital LP lifted its position in shares of Heron Therapeutics by 1,033.1% during the 3rd quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock valued at $12,238,000 after acquiring an additional 8,855,361 shares during the period. Millennium Management LLC boosted its stake in shares of Heron Therapeutics by 2,785.2% during the 4th quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock worth $9,321,000 after acquiring an additional 6,921,405 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Heron Therapeutics in the 3rd quarter worth approximately $5,357,000. Tang Capital Management LLC grew its holdings in shares of Heron Therapeutics by 81.2% in the 4th quarter. Tang Capital Management LLC now owns 6,250,000 shares of the biotechnology company’s stock worth $8,125,000 after acquiring an additional 2,800,000 shares during the period. Finally, Citigroup Inc. increased its stake in Heron Therapeutics by 4,666.9% in the 3rd quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock valued at $3,120,000 after purchasing an additional 2,424,576 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.